(ENTX) – Why Entera Bio’s Stock Is Surging Higher Today

(ENTX) – Why Entera Bio’s Stock Is Surging Higher Today

Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher on heavy volume Friday after the company announced the Phase 2 clinical trial of EB613 met its primary endpoint.
According to Entera, EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, drug candidate positioned as the first potential once daily, oral, bone building (anabolic) treatment for osteoporosis…

Read More from www.benzinga.com

The best source of news - newszf.com
Logo
Compare items
  • Total (0)
Compare
0